Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bcl-2 Expression as a Predictive Marker of Hormone-Refractory Prostate Cancer Treated with Taxane-Based Chemotherapy

15 Oct 2006

Abstract excerpt

PURPOSE: Bcl-2 inhibits apoptosis, and its overexpression is associated with hormone refractory prostate cancer (HRPC). Bak and Bax are in the Bcl-2 family and counteract the antiapoptotic function of Bcl-2. Taxane-induced (paclitaxel and its analogue docetaxel) phosphorylation of Bcl-2 abolishes the potential antiapoptotic effect of Bcl-2. We hypothesized that (a) survival benefit in HRPC patients treated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell death mechanisms and regulation
Share to Prostate Cancer Diagnosis and Treatment
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17062688
DOI: 10.1158/1078-0432.ccr-06-0147

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bcl-2 Expression as a Predictive Marker of Hormone-Refractory Prostate Cancer Treated with Taxane-Based ChemotherapyPMID 17062688Read ↗

Prognostic relevance of Bcl‐2 overexpression in surgically treated prostate cancer is not caused by increased copy number or translocation of the geneSemantic proximity Read ↗

Taxane induces attenuation of the CXCR2/BCL-2 axis and sensitize prostate cancer to platinum-based treatmentsSemantic proximity Read ↗

Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers.Semantic proximity Read ↗

Chemosensitization of Prostate Cancer by Modulating Bcl-2 Family ProteinsSemantic proximity Read ↗

BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticitySemantic proximity Read ↗

Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak.Semantic proximity Read ↗

Prognostic significance of Bcl-2 in clinically localized prostate cancer.Semantic proximity Read ↗

TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.Semantic proximity Read ↗

Differential gene expression of BCL‐2, ZEB2‑AS1 and BALR‐2 in prostate cancer and benign prostatic hyperplasiaSemantic proximity Read ↗

Mutations in BRCA2 and taxane resistance in prostate cancer.Semantic proximity Read ↗

Truncated Bcl-2, a potential pre-metastatic marker in prostate cancer.Semantic proximity Read ↗

Correlation of p53 protein accumulation and Bcl-2 overexpression with histopathological features in prostatic cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.